Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Tandem Diabetes Care, Inc.
Type
Public
Traded as NASDAQ: TNDM
Founded San Diego, California 2006 (2006)
Headquarters San Diego, California, United States
Number of employees
437
Website www.tandemdiabetes.com

Tandem Diabetes Care is a public US medical device manufacturer based in San Diego, CA. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.

In 2006, a group of engineers recognized the need for new and improved methods of pumping insulin and incorporated as Phluid, Inc. In 2007, Kim Blickenstaff joined the organization as President and CEO, bringing his philosophy of using market research as the inspiration for product development and started on the development of the t:slim Insulin Pump. In 2008, this predecessor company became the newly incorporated Tandem Diabetes Care, Inc. that was formed with a focus on promoting a comprehensive, user-centric, and integrated approach to diabetes product development and customer care. Tandem Diabetes Care felt that incorporating enhanced ease of use and attractive design—often associated with consumer electronics development—would also encourage more patients to consider the clinical benefits of insulin pump therapy. Tandem Diabetes Care interviewed more than 4,000 insulin pump users and health care providers to design its first device, the t:slim Insulin Pump.

In 2016, the company was ranked #39 on the Deloitte Fast 500 North America list.

In November 2011, the company received FDA clearance to market the t:slim Insulin Pump, the first ever touch-screen insulin pump. In February 2013, the company received FDA clearance to market the t:connect Diabetes Management Application, a Mac and PC-compatible data management application that provides t:slim Pump users and their healthcare providers a way to display data from the pump and supported blood glucose meters on a cloud-based platform. In January 2015, Tandem announced FDA clearance of the t:flex Insulin Pump, the largest capacity insulin pump on the market. In July 2014, Tandem announced that it had submitted a PMA for the t:slim G4, which integrates t:slim Pump technology with the Dexcom G4 Platinum CGM System. This device was approved by the FDA in September 2015. The FDA approved a tool to update the software on Tandem's pumps in July, 2016. The Tandem Product Updater is designed to deliver software updates to Tandem's pumps to provide new features and interface improvements. In announcing the approval, Tandem stated that the first use of the new tool will be to update t:slim pumps which were shipped prior to April, 2015 with a new version of the firmware which speeds the loading process and offers other enhancements. In late October 2016, Tandem began shipping its next-generation pump platform, the t:slim X2. The X2 will receive updates via the Tandem Product Updater product, with planned updates initially including integration with Dexcom's G5 and G6 Continuous Glucose Monitors, and eventually the integration of closed-loop technology which Tandem licensed from TypeZero in July 2016.


Investment goal date:
Dividends reinvested
Tandem Diabetes Care, Inc. TNDM report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-30
--
--
Q4 2017
2018-03-06
--
--
Q3 2017
2017-10-26
-3.5900
-3.1000
Q2 2017
2017-07-27
-4.3000
-4.4000
Q1 2017
2017-04-27
-7.7000
-7.5000
Q4 2016
2017-03-08
-5.5500
-4.8000
Q3 2016
2016-11-01
-7.4000
-9.7000
Q2 2016
2016-07-28
-6.0000
-6.0000
Q1 2016
2016-04-28
-6.8000
-6.8000
Q4 2015
2016-02-24
-4.0000
-4.0000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Apex Capital Management
975614
BLACKROCK ADVISORS LLC
10400
BlackRock Fund Advisors
604834
BlackRock Institutional Trust Company, N.A.
331904
BlackRock Investment Management, LLC
75852
MANAGED ACCOUNT ADVISORS LLC
269101
Platte River Capital LLC
23080
RUSSELL FRANK CO/
73728
Schonfeld Group Holdings LLC
11979
Major Shareholders
Name Relationship
Total Shares
Holding stocks
GREENE HOWARD E JR
0.5000% (117865)
TNDM /
TREU JESSE I
0.2300% (54390)
BLAIR JAMES C
0.2300% (54390)
CAHILL EDWARD L
7.4100% (1739154)
MASI / TNDM /
VITULLO NICOLE
0.2300% (54390)
DOVEY BRIAN H
0.2300% (54390)
SCHOEMAKER KATHLEEN K
0.2300% (54390)
BLICKENSTAFF KIM D
1.7400% (407939)
MDVN / TNDM /
TWOMEY CHRISTOPHER J
0.0700% (17572)
CADX / SNMX / TNDM /
SMITH LONNIE M
0.6400% (149200)
ISRG / TNDM /
ROEDER DOUGLAS A
0.1500% (35467)
TNDM /
HLM VENTURE PARTNERS II, L.P.
6.2000% (1454058)
TNDM /
Anacone Robert
0.0100% (2811)
TNDM /
Halak Brian K
0.2300% (54390)
Sheridan John F
0.1000% (22763)
TNDM /
DP VII ASSOCIATES LP
0.2300% (54390)
DOMAIN PARTERS VII L P
13.5900% (3189058)
BERGER DAVID B
0.0200% (4330)
SNMX / TNDM /
Delphi Management Partners VIII, L.L.C.
0.1500% (35467)
BAXS / TNDM /
TPG Group Holdings (SBS) Advisors, Inc.
10.6400% (2496194)
Allen Dick
0.5600% (131598)
TNDM /
Cajigas John
0.0100% (2691)
TNDM /
% ()